This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Smith, K. L. Articles by Robson, M. Search for Related Content PubMed PubMed Citation Articles by Smith, K. L. Articles by Robson, M.

BRCA Mutations in Women with Ductal Carcinoma In situ

Authors' Affiliations: Departments of ¹ Medicine and ² Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, and ³ VU University Medical Center, Amsterdam, the Netherlands

Requests for reprints: Mark Robson, Clinical Genetics Service, Memorial Sloan-Kettering Cancer Center, 222 East 70th Street, New York, NY 10021. Phone: 212-434-5129; Fax: 212-434-5166; E-mail: robsonm{at}mskcc.org.

Purpose: The strength of the association between ductal carcinoma in situ (DCIS) and BRCA mutations has not been defined.

Experimental Design: Mutation frequency was compared in three groups: (1) a prevalent series of women with DCIS, (2) an incident series of women with DCIS, and (3) a clinic-based series of women with DCIS referred for hereditary cancer risk assessment. In groups 1 and 2, limited to Ashkenazi Jewish (AJ) cases, mutation frequency was compared with that in age-matched AJ controls with invasive breast cancer (IBC).

Results: In group 1, 3 of 62 (4.8%) women with DCIS and 15 of 130 (11.5%) controls with IBC had BRCA mutations. In group 2, 0 of 58 (0%) women with DCIS and 6 of 116 (5.2%) controls with IBC had BRCA mutations [combined odds ratios (OR) in groups 1 and 2: 3.64, 95% confidence interval (95% CI), 1.06-12.46; P = 0.04]. In group 3, deleterious mutations were identified in 10 of 79 (12.7%) probands with DCIS, similar to the frequency in IBC probands. In group 3, mutations were associated with family history of ovarian cancer (OR, 13.35; 95% CI, 2.48-71.94; P = 0.003) or early onset breast cancer (OR, 16.23; 95% CI, 1.68-157.01; P = 0.02) but not with AJ ethnicity or age at diagnosis.

Conclusions: BRCA mutations were less frequent in women with DCIS not selected for family history or age at diagnosis than in women with IBC. Nonetheless, mutations were found in a significant proportion of women with DCIS who presented for hereditary risk assessment.